Oxalyl chloride → N-(4-(tert-Butylamino)quinazolin-8-yl)-6-chloro-2-fluoro-3-(pivalamidomethyl)benzamide
Reaktionsgleichung
[C:1]([NH:5][C:6]1[C:15]2[C:10](=[C:11]([NH2:16])[CH:12]=[CH:13][CH:14]=2)[N:9]=[CH:8][N:7]=1)([CH3:4])([CH3:3])[CH3:2].[Cl:17][C:18]1[C:23]([C:24](O)=[O:25])=[C:22]([F:27])[C:21]([CH2:28][NH:29][C:30](=[O:35])[C:31]([CH3:34])([CH3:33])[CH3:32])=[CH:20][CH:19]=1.C(Cl)(=O)C(Cl)=O.CCN(C(C)C)C(C)C>CN(C=O)C.C(Cl)Cl>[C:1]([NH:5][C:6]1[C:15]2[C:10](=[C:11]([NH:16][C:24](=[O:25])[C:23]3[C:18]([Cl:17])=[CH:19][CH:20]=[C:21]([CH2:28][NH:29][C:30](=[O:35])[C:31]([CH3:32])([CH3:33])[CH3:34])[C:22]=3[F:27])[CH:12]=[CH:13][CH:14]=2)[N:9]=[CH:8][N:7]=1)([CH3:4])([CH3:2])[CH3:3]Komponenten
7
Edukt 4
Produkt 1
Reagenzien, Katalysatoren, Lösungsmittel 2
Versuchsvorschrift
The title compound was prepared following the procedure described in Example-1 using N4-(tert-butyl)quinazoline-4,8-diamine (Intermediate-55, 100 mg, 0.46 mmol), 6-chloro-2-fluoro-3-(pivalamidomethyl)benzoic acid (Intermediate-2, 146 mg, 0.51 mmol), oxalyl chloride (126 mg, 0.99 mmol), DMF (1 drop) and DIPEA (132 mg, 1.03 mmol) in CH2Cl2 (3 mL) to afford 30 mg of the title product. 1H NMR (400 MHz, DMSO-d6): δ 10.39 (s, 1H), 8.69-8.67 (d, J=7.4 Hz, 1H), 8.51 (s, 1H), 8.18-8.16 (m, 2H), 7.54-7.50 (t, J=8.0 Hz, 1H), 7.44-7.40 (m, 2H), 7.37-7.33 (t, J=8.0 Hz, 1H), 4.32-4.30 (d, J=6.0 Hz, 2H), 1.56 (s, 9H), 1.14 (s, 9H); MS (m/z): 486.25 (M+H)+.
Aufarbeitung
- customThe title compound was prepared
Quellen und Nachweise
- ORD-Eintrag
- ord-0682d24788bf4c55a1e24deae7814921
- Quelldatensatz
- uspto-grants-2015_04
- Patentnummer
- US09006257B2
Notizen zur Reaktion
Wird geladen…